Behaviour modification and benign prostatic hyperplasia: replacement for medications.

Curr Opin Urol

Department of Urology, St. Bartholomews Hospital, Barts and London NHS Trust, West Smithfield, London, UK.

Published: January 2010

Purpose Of Review: Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is a highly prevalent chronic disease. The cost impact of treatment is high. The field of behavioural treatments which could be suitable in the majority of uncomplicated patients has rarely been assessed. We summarize the recent knowledge and data from behavioural interventions chiefly the randomized controlled trial (RCT) of a self-management programme for BPH.

Recent Findings: The self-management RCT has revealed that a rigorously structured behavioural programme can significantly reduce lower urinary tract symptoms severity and decrease objective symptoms like nocturia, urgency and frequency compared with standard care alone. The elements of the programme and their behavioural framework are carefully defined. The basis of the programme's effectiveness is yet unknown, but may involve changes in bladder capacity rather than simple fluid management. The sphere of behavioural interventions for BPH is lacking and requires more research.

Summary: Elements of the self-management programme are already being used in watchful waiting. Improving quality of life of patients with BPH through self-management will help patients and may reduce the financial burden on healthcare systems. The promotion of multidisciplinary team is a key step in implementing self-management strategies. With larger scale trials, the limitations raised and questions posed by the RCT can be further addressed.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0b013e32833307c6DOI Listing

Publication Analysis

Top Keywords

benign prostatic
8
prostatic hyperplasia
8
lower urinary
8
urinary tract
8
tract symptoms
8
behavioural interventions
8
self-management programme
8
behavioural
5
self-management
5
behaviour modification
4

Similar Publications

Introduction: Macrophages exhibit marked phenotypic heterogeneity within and across disease states, with lipid metabolic reprogramming contributing to macrophage activation and heterogeneity. Chronic inflammation has been observed in human benign prostatic hyperplasia (BPH) tissues, however macrophage activation states and their contributions to this hyperplastic disease have not been defined. We postulated that a shift in macrophage phenotypes with increasing prostate size could involve metabolic alterations resulting in prostatic epithelial or stromal hyperplasia.

View Article and Find Full Text PDF

Background: We compared the safety and efficacy of holmium laser enucleation of the prostate (HoLEP) and transurethral resection of the prostate (TURP) in elderly men (aged ≥75 years) with benign prostatic hyperplasia (BPH).

Methods: A retrospective analysis of 151 patients (HoLEP: 72; TURP: 79) was conducted. Preoperative and postoperative parameters, including prostate size, International Prostate Symptom Score (IPSS), catheterization duration, hospital stay, and perioperative complications (incontinence and dysuria), were analyzed.

View Article and Find Full Text PDF

Giant prostatic calculus in patient treated with perineal prostatotomy: case report.

AME Case Rep

November 2024

Department of Urology, São José do Rio Preto Regional Faculty of Medicine Foundation (FUNFARME), São José do Rio Preto, SP, Brazil.

Background: Urolithiasis (kidney stone) is a common condition that often leads patients to urgent or emergency care services. Urinary calculi are generally found in the kidneys, ureters, or bladder. Urethral calculi are uncommon and can result from the migration of a calculus in the upper urinary tract or vesicle or may be primary of the urethra.

View Article and Find Full Text PDF

Background: Fibromatosis of the breast, also known as desmoid-type fibromatosis (DTF), is a rare tumor marked by the development of non-metastatic, locally aggressive tumors in breast tissue. It represents only 0.2% of all breast tumors.

View Article and Find Full Text PDF

[A comparative study on the diagnostic value of F-PSMA PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer].

Zhonghua Yi Xue Za Zhi

January 2025

Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing100730, China.

To compare the diagnostic value of fluorine 18-labelled prostate-specific membrane antigen (PSMA) PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer (csPCa). The data of 70 patients with prostate cancer who underwent radical prostatectomy at Beijing Hospital from February 1, 2019 to February 29, 2024 were retrospectively analyzed. All patients underwent whole body F-PSMA PET/CT examination before surgery and pathological large sections of prostate specimens were made after surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!